Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I suggest you to read my old posts ...
LINK:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93058398
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93063403
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93087550
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93078591
.
I am sorry, but I think it's unnecessary to talk about it because it is obvious, however:
1) At the pipeline Intellect would be added, the drug CHF 5074, in Phase 2 and Phase 3 soon ...
2) Dr. Chain again become the CEO of Intellect ...
3) Possible new name after the merger of the two companies, with the presentation of an IPO on the NASDAQ OTC ... ( great pipeline and great CEO )
All this was not enough?
.
It is significant:
represented CereSpir in negotiating this transaction.
It is not written:
will represent CereSpir in negotiating this transaction.
-----------------------------------------------------
Therefore, I believe that they have already entered into a definitive agreement between Chiesi Pharma and CereSpir.
Otherwise it would not make sense, publish an update without a result.
Before, CereSpir was an empty box with a web site.
Starting today, we can expect at any time the merger between Intellect and CereSpir with CEO Dr. Chain ( this is what I think ).
.
Update by CereSpir
November 8, 2013 – New York, NY
... represented CereSpir in negotiating this transaction.
http://www.cerespir.com/110813.htm
.
Clarification re PFE’s potential split-up into three companies: Management has committed to separating the internal management into three operating groups during 2014, which is a prerequisite for a split-up; however, PFE has not yet made any commitment as to whether it will actually proceed with a split-up.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93697345
.
Thanks for sharing !
Without updates, we can only try to make the most likely hypothesis.
I think too many months have elapsed to make a partnership, merger, sale, ... also with consultation of Evli.
Therefore, I believe that:
1) They are working on IPO between CereSpir and Intellect. (IPO requires a lot of work and time required to be met).
2) They are waiting for the results of clinical trials of Pfizer for "Ponezumab." In case of positive results could follow a partnership or other ...
Identical reasoning for Viropharma with VP 20629 ...
3) Both steps 1 + 2
.
Probably, you did not read the post dated October, 28 and 29 ...
Big news is that Dr. Frost as CONSULTANT and shareholder of BZNE
Seeking Alpha does not say it ...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93461762
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93476597
.
It is evident to all that the stock ILNS is manipulated ... without need my opinion.
How you feel, it may also happen that the Company dump more shares into the count.
I considered all the pros and cons, and I hold tight to me my dear shares.
If I lose my money invested in ILNS, at least I will have the satisfaction of having made a contribution to research in the fight against Alzheimer's Disease.
Whatever happens, manipulation, dumping shares, Reverse Split R/S, etc. ... I am confident in Dr. Chain and Evli.
I believe that they are doing a great job and in great silence.
Example:
An IPO (Initial Public Offering) requires many months to be ready for the market.
I am of the opinion that more will lengthen the waiting time of the shareholders and the greater will be the final surprise ...
.
... If that email Tencoin posted was in fact real ..
--------------------------------------------------------------------------------------------
I received reply by Mr. Maza 10 minutes before my post dated October 31:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93598851
More:
I asked to Mr. Maza update for day October 30 for Pfizer lawsuit ...
He sent me back reply about one hour later !
.
Suite 101 ( the same room for ILNS and BZNE - probably the place of work of Mr. Maza )
---------------------------------------------------------------------
Form 8-K for INTELLECT NEUROSCIENCES, INC.
12-Aug-2013
Other Events, Financial Statements and Exhibits
Item 8.01. Other Events.
On July 30, 2013, Intellect Neurosciences, Inc. (OTCBB: ILNS) issued a press release announcing that it has retained Dr. Daniel Chain, though Chain Pharmaceuticals LLC, as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction. Dr. Chain, Intellect's founder, former Chairman and CEO, inventor of the company's technology platforms and developer of its ongoing programs, is uniquely qualified to assist the company in its efforts to maximize the value of Intellect's unique collection of high value assets.
In connection with the engagement of Chain Pharmaceuticals, LLC, the company and Dr. Chain entered into mutual releases of all claims against each other, in particular, a release by the company of Dr. Chain from any claim related to Dr. Chain's involvement with the development of CHF5074, a drug product candidate designed as a treatment for early stage Alzheimer's disease. CHF5074 is currently owned by Chiesi Farmaceutici S.p.A., a pharmaceutical company based in Parma, Italy.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished as part of this Report on Form 8-K:
99.1 Press Release dated July 30, 2013
http://biz.yahoo.com/e/130812/ilns8-k.html
----------------------------------------------------------------------------------
About CereSpir Incorporated
CereSpir is dedicated to preserving the primary essence of each person, his or her memories. The privately held company was founded by Daniel Chain, PhD, to focus exclusively on the final development of CHF 5074, upon the completion of a licensing agreement with Chiesi Farmaceutici S.p.A. Dr. Chain is a seasoned, accomplished and knowledgeable entrepreneur, inventor and CEO who has spearheaded the development of several innovative therapeutic approaches in his unrelenting pursuit of a world without Alzheimer's disease.
http://www.cerespir.com/072613b.htm
----------------------------------------------------------------------------
... Dr.Chain to focus exclusively on the final development of CHF 5074 ...
and
... in particular, a release by the company of Dr. Chain from any claim related to Dr. Chain's involvement with the development of CHF5074 ...
-----------------------------------------------------------------------------
I believe that it has only one meaning:
CereSpir and Intellect is only one Company, with Dr. Chain as CEO !
.
When the manipulators want the avalanche effect, these downfalls also occur with big stocks.
Many shareholders sell for fear of losing everything, others sell thinking of buy back later at lower prices ...
Unfortunately, most of these shareholders remain burned of the experience ... the day after, the stock reaches the stars and they cannot buy anymore ...
NOTE:
I don't know who these manipulators, however, they are informed about upcoming developments and are acting in their interest.
.
I sent an email to Dr. Maza about Pfizer lawsuit.
He replied :
I am not aware any Pfizer update.
------------------------------------------------
It is very strange !
.
LONZA - Business Performance Remains on Track
Pharma&Biotech Market Segment
Driven by the state-of-the-art technology toolbox, the Pharma&Biotech market segment continues to generate customer interest. In Custom Manufacturing, the pipeline development for long term assets commitment is on track and the business also secured new contracts for small molecule products.
The build-out of additional commercial scale Antibody Drug Conjugate (ADC) capacity in Visp is on track in response to continuous high demand for a full service integrated ADC offering, from mAb manufacture to conjugation.
In the first 3 quarters of 2013 Lonza underwent 16 regulatory inspections and follow-up discussions with regulatory agencies for both products and sites.
The phasedown of our Hopkinton, MA (USA) site is on track.
http://www.lonza.com/about-lonza/media-center/news/2013/q3-2013-results-e.aspx
.
I noticed that you are very upset ...
Did you phoned or sent emails to Dr. Maza, to know about the lawsuit of yesterday ?
.
VP-20629 for Friedreich's Ataxia
We initiated a single and multiple oral dose safety and tolerability study in patients in 2013. The company anticipates completion of enrollment in the first half of 2014.
Date: 10/31/2013
http://ih.advfn.com/p.php?pid=nmona&article=59817871
.
Has somebody tried to buy from $ 0.006 to 0.007 ?
I think nobody small investor can buy at these low prices.
The manipulators sell-off shares at $ 0.006 and then buy back immediately.
These maneuvers serve only to turn down the price and scare the shareholders ...
.
The great manipulators are trying to scare the small shareholders ...
Who can buy, take advantage now !
You do as Buffett ...
------------------------------------------------------
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”
Warren Buffett
Warren Edward Buffett is an American investor, industrialist and philanthropist. He is widely regarded as one of the most successful investors in the world. Often called the "legendary investor, Warren Buffett", he is the primary shareholder, chairman and CEO of Berkshire Hathaway. He is consistently ranked among the world's wealthiest people. He was ranked as the world's wealthiest person in 2008 and is the third wealthiest person in the world as of 2011.
Buffett is called the "Oracle of Omaha" or the "Sage of Omaha" and is noted for his adherence to the value investing philosophy and for his personal frugality despite his immense wealth. Buffett is also a notable philanthropist, having pledged to give away 99 percent of his fortune to philanthropic causes, primarily via the Gates Foundation. He also serves as a member of the board of trustees at Grinnell College.
.
Could be ILNS added to the list?
OPKO’s growth strategy includes investing in early-stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder. Some of our most recent investments include:
BioZone ( Dr. Maza as CEO ) + ... more
http://www.opko.com/strategic-investments/overview/
.
I looked for the number of retail shareholders of ILNS, unfortunately without success.
I would like to make an estimate about the number of shares and the potential present value.
Usually before a thunder is observed a flash ...
Probably big speculators try to scare us ILNS retail shareholders.
They maneuver the stock downward, to buy before take-off.
Considering about 100 retail shareholders ILNS with an average of 500,000 shares each, we get a total of about 50 million shares.
If 20% of the shareholders ILNS sell their shares for fear, the great manipulators will do a great deal from $ 0.007 to at least $ 0.1 or $ 1 per share.
NOTE:
Has someone data updated on the number of shares held by retail shareholders?
.
You said: I think Dr. Frost sold a lot of his shares (BZNE).
He is a consultant and shareholder of BZNE, so he sells and buys when the stock is cheap.
We all want to be in the place of Dr. Frost as shareholders ...
Act as consultants to the Company and know in advance the movements of the market ...
It is like printing real banknotes $ 100 with the copier ...
The important thing is that Dr. Frost is consultant of BZNE and knows the power of INTELLECT.
Drs. Frost and Chain are skilled businessmen and I expect great developments from their cooperation ...
.
There are two good news that make well hope ...
1) Dr. Frost provides us (BZNE) with strategic guidance and business development opportunities.
2) OPKO Health and TEVA Pharmaceutical have the same pipeline of Intellect.
Intellect is connected with Biozone at the same address.
Dr. Frost is connected with Biozone, with Teva and OPKO - as shareholder and consultant (BZNE), such as CEO of Teva and OPKO.
So 1 + 1 = 2 ...
About Dr. Maza, I don't know answer now.
.
Likely interplay between ILNS and BZNE+TEVA+OPK
Opko Health ( NYSE: OPK )
http://www.opko.com/
.
Likely interplay between ILNS and BZNE + TEVA + OPK
Opko Health ( NYSE: OPK )
http://www.opko.com/
.
Likely interplay between: ILNS + BZNE + TEVA
Company Profile
http://www.biozonelabs.com/
BioZone Laboratories, Inc., formed in 1987 by Dr. Brian Keller, has operated since inception as a developer, manufacturer and marketer of over-the-counter drugs and preparations, cosmetics and nutritional supplements. BioZone has developed hundreds of products throughout its history and sold millions of units. The company's strong customer base is made up of large, well-known industry leaders.
In 2011, BioZone Laboratories, Inc. was acquired by BioZone Pharmaceuticals, Inc., a publicly traded corporation.
Dr. Phillip Frost, Chairman and CEO of OPKO Health Inc. and Chairman of TEVA Pharmaceutical Industries, the world’s largest manufacturer and distributor of generic drugs, is a significant shareholder of BioZone Pharmaceuticals.
Dr. Frost provides us with strategic guidance and business development opportunities. BioZone Pharmaceutical’s stock price is quoted on the OTCBB under the symbol “BZNE”.
http://www.tevapharm.com/About/BoardOfDirectors/Pages/default.aspx
.
Change of address
I give you my congratulations: you are like a hound dog ...
The change of address took place between September 25 and October 15, as it is indicated in the files 10-k.
I think that the reasons could be at least two:
1) Dr. Maza works for Intellect and Biozone, so for his convenience he chosen the same address.
2) Intellect is moving behind the scenes and don't want to introduce the new place or new Company. Therefore, Dr. Maza chosen a provisional place for Intellect.
3) ???
I think that Intellect and Biozone have too different pipeline, and I don't see a merger ...
However, for further details you can type the address on Google / map: 550 Sylvan Avenue, Englewood Cliffs, NJ
You will see an anonymous building with 2 floors, with the main entrance on 4 Demarest Avenue, Englewood Cliffs, NJ
Website: http://www.biozonelabs.com/
.
IPO Activity
I hope to find the name of Intellect, CereSpir, or new name of the Company ...
I try several times a day on the following links:
http://www.nasdaq.com/markets/ipos/activity.aspx?tab=filings
http://www.nasdaq.com/markets/ipos/activity.aspx?tab=upcoming
90 million extra shares issued which dilutes the value of the stock.
Shares Outstanding = 285.82 million
The number of shares held by investors and Company in siders, excluding dilutive securities such as non-vested RSUs and unexercised options.
http://www.google.com/finance?q=OTCMKTS%3AILNS&ei=yM1gUuDCCZLDwAOCWg
.
.
I believe that no matter the method of financing, LBO or BCLOC.
I think it's important that Dr. Chain has obtained funding for the New Company CereSpir.
Maybe behind the scenes (thanks to Evli), the New Company has already been created, with Dr. Chain as CEO.
I hope that the New Company is organized as follows:
Dr. Chain as CEO, new funding obtained, conclusion of contract with Chiesi Pharma to CHF 5074 and imminent transition to the phase 3 study, the merger has already taken place between CereSpir and Intellect, forthcoming IPO on Nasdaq.
.
The leveraged buyout or LBO is a structured finance operation used for the acquisition of a company by the exploitation of the borrowing capacity of the company. Leveraged buyout transactions are characterized by a high flexibility in the operating modes with which are carried out , the participants and the set of sources of financing used .
The leveraged buyout usually involves the creation of a special purpose vehicle set up ad hoc and called NewCo ( CereSpir ) , in which the sponsors of the operation and the various lenders entering the venture capital and debt capital necessary for the acquisition .
Identifiable are two general schemes by which are made LBO :
1 . acquisition by merger : then proceed with a merger between the target company ( the merged company) and NewCo (merging ) ;
2 . assets salt : The company Newco does not buy the target company as a whole but only those assets.
This can have as investors :
• Management of the company ( management buyout )
• Management of other companies ( Management buyin )
and allows you to join the company not only through capital , but also through debt .
The debt contract is then generally repaid or cash flows generated by the acquired company or by selling branches (or non-strategic business unit ) . In the latter case there is also talk of break-up.
.
My theory could be NOT confirmed, however:
The reference price will be determined by the new shares that will placed on the market.
If it will be so, it will need to wait until the date of the placement to know the price of a new share.
Therefore, each of the old shareholders will be free to sell immediately at a price lower than the IPO price.
Or, wait, hope for a rise, and sell later ...
.
My theory could not be confirmed, however:
The reference price will be determined by the new shares that will placed on the market.
If it will be so, it will need to wait until the date of the placement to know the price of a new share.
Therefore, each of the old shareholders will be free to sell immediately at a price lower than the IPO price.
Or, wait, hope for a rise, and sell later ...
.
I P O
I feeling that soon will be announced an IPO (Initial Public Offering ).
CereSpir with CEO Dr. Chain (+ CHF 5074), will buy INTELLECT ( maybe bought it ).
The New Company will be offering (IPO) at least $ 1 per share.
The existing shareholders' shares will likely be auctioned, while the new shares will be offered for sale at a price of at least $ 1.
Good luck to me and all ILNS shareholders ( the shorter will die of envy) ...
.
Buying shares is simple!
The problem is to understand: who SELLS OFF and WHY ...
They are not retail shareholders!
.
Another stock like ILNS would be 10 cents with today's volume ...
.
13,500,000 shares, now it is clear, sellers can be either Mr. Blech or Intellect.
Mr. Blech is not stupid to sell now at this price ...
In addition, none of the shareholders on this board would sell their shares at this price.
Intellect can sell these shares at this price, they did not pay anything and can also give as a gift to new shareholders.
Question to all shareholders:
Why wants Intellect to keep the price down for their own shares?
.
I would like buy more shares but I fear new R/S ( Reverse Split ) 1 to 50 or more ...
The shares are not coming from the moon ...
I do not understand who are the big sellers-off ...
They give shares as a gift ...
WHY ?
It is good sign!
This means that CereSpir (CEO Dr. Chain) acquired before CHF5074 by Chiesi Pharma and then bought ILNS (shares and patents).
How will be worth CereSpir on Stock Market?
.
I suggest you read about Phase Ib Trial Design :
The Complete Phase Ib Trial Design - An Approach for Getting to Phase II Faster
http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design/
.
Updated - Phase 1b testing
Status
ViroPharma has completed Phase 2-enabling toxicology studies with VP 20629, and has initiated Phase 1b testing in patients with Friedreich's ataxia.
http://www.viropharma.com/pipeline/vp20629.aspx
.